Zoetis

Current directors and officers who also hold a role at another S&P 500 company.

• Frank A. DamelioHPE · DirectorHUM · DirectorVTRS · Director
• Gavin HattersleyMKC · Director
• James SaccaroGEHC · CFO
• Kristin C. PeckBLK · Director
• Michael B. McCallisterT · Director
• Rimma DriscollDXCM · Director
• Stephanie TileniusSTX · Director
• Vanessa BroadhurstJNJ · Officer

Latest Schedule 13D/13G filing per holder. Holders that reported falling below 5% are not shown. Index funds usually report once a year.

No 5% holder filings parsed yet for this company.

Open-market purchases and sales reported on Form 4. Grants, option exercises and tax withholding are excluded.

Every 8-K with Item 5.02 (departure, election or appointment of directors and officers). The text is the first paragraph of the item.

1. Oct 13, 2026

   On October 8, 2026, the Board of Directors (the "Board") of Zoetis Inc. (the “Company”) appointed Iris Knobloch to the Board, effective as of December 1, 2026, to serve in such capacity until her successor is appointed or qualified or until her resignation or removal. In connection with the appointment of Ms. Knobloch, the size of the Board will be increased from twelve to thirteen members effective as of December 1, 2026. Ms. Knobloch has been appointed to serve on the Board’s Corporate Governance Committee. Ms. Knobloch was not appointed to the Board pursuant to any arrangements or understandings with any third party, and since the beginning of the last fiscal year, there have been no related party transactions between the Company and Ms. Knobloch that would be reportable under Item 404(a) of Regulation S-K.

   Read the 8-K filing
2. Aug 6, 2026

   Appointment of James Saccaro as Executive Vice President, Chief Financial Officer and Chief Operating Officer On August 6, 2026, Zoetis Inc. (the “Company”) announced that James Saccaro has been appointed as Executive Vice President, Chief Financial Officer and Chief Operating Officer, effective August 17, 2026. Mr. Saccaro will lead Zoetis’ global finance function, shaping capital allocation, financial strategy, reporting and controls, and investor engagement and oversee Global Manufacturing and Supply to drive operational execution and performance. He will serve as the principal financial officer and principal accounting officer of the Company. Mr. Saccaro, age 53, has served as Vice President and Chief Financial Officer of GE HealthCare Technologies Inc. since June 2023. He previously served as Executive Vice President and Chief Financial Officer of Baxter International Inc.

   Read the 8-K filing
3. May 22, 2026

   Effective May 20, 2026, Ms. Louise M. Parent retired from the Board of Directors of Zoetis Inc. (the “Company”), prior to the Company’s 2026 Annual Meeting of Shareholders (the “Annual Meeting”) in accordance with the Company’s director retirement policy.

   Read the 8-K filing
4. Oct 28, 2025

   On October 23, 2025, the Board of Directors (the "Board") of Zoetis Inc. (the “Company”) appointed Stephanie Tilenius to the Board, effective as of December 1, 2025, to serve in such capacity until her successor is appointed or qualified or until her resignation or removal. In connection with the appointment of Ms. Tilenius, the size of the Board will be increased from twelve to thirteen members effective as of December 1, 2025. Ms. Tilenius was not appointed to the Board pursuant to any arrangements or understandings with any third party, and since the beginning of the last fiscal year, there have been no related party transactions between the Company and Ms. Tilenius that would be reportable under Item 404(a) of Regulation S-K.

   Read the 8-K filing
5. May 22, 2025

   Effective May 21, 2025, Mr. Robert Scully retired from the Board of Directors of Zoetis Inc. (the “Company”), prior to the Company’s 2025 Annual Meeting of Shareholders (the “Annual Meeting”) in accordance with the Company’s director retirement policy. Effective May 21, 2025, Dr. Mark Stetter was elected to the Board of Directors of the company at the Annual Meeting. On May 22, 2025, the Company issued a press release announcing the election of Dr. Stetter. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

   Read the 8-K filing
6. May 24, 2024

   On May 20, 2024, in connection with Heidi C. Chen’s previously announced separation, Zoetis Inc. (the “Company”) entered into a Letter Agreement (the “Letter Agreement”) with Ms. Chen. The Letter Agreement provides that Ms. Chen will continue employment as a non-corporate officer employee of the Company through July 16, 2024 (the “Termination Date”), and through the Termination Date will continue receiving her current annual base salary and employment benefits. After the Termination Date Ms. Chen will serve as a non-employee consultant through December 31, 2024, and in exchange for such advisory services, and subject to compliance with the terms of the Letter Agreement and the execution of a release agreement, Ms. Chen will receive a consulting fee of $350,000. Ms.

   Read the 8-K filing
7. May 23, 2024

   Effective May 21, 2024, Dr. Linda Rhodes retired from the Board of Directors of Zoetis Inc. (the “Company”), prior to the Company’s 2024 Annual Meeting of Shareholders (the “Annual Meeting”) in accordance with the Company’s director retirement policy.

   Read the 8-K filing
8. Apr 16, 2024

   Effective April 16, 2024, Heidi C. Chen will cease her role as Executive Vice President, General Counsel and Corporate Secretary, and Business Lead of Human Health Diagnostics of Zoetis Inc. (the “Company”). Ms. Chen will continue as an employee advisor of the Company through July 16, 2024, after which time it is anticipated she will serve as a non-employee consultant. Roxanne Lagano, Executive Vice President, Chief Human Resources Officer and Global Operations, will serve as interim General Counsel and Corporate Secretary while the Company conducts a search for Ms. Chen’s permanent replacement. The Company is currently working to identify external and internal candidates. Ms.

   Read the 8-K filing
9. Apr 1, 2024

   On April 1, 2024, the Board of Directors (the "Board") of Zoetis Inc. (the “Company”) appointed Gavin D.K. Hattersley to the Board, to serve in such capacity until his successor is appointed or qualified or until his resignation or removal. In connection with the appointment of Mr. Hattersley, the size of the Board was increased from twelve to thirteen members. Mr. Hattersley will serve on the Board’s Corporate Governance and Sustainability Committee. Mr. Hattersley was not appointed to the Board pursuant to any arrangements or understandings with any third party, and since the beginning of the last fiscal year, there have been no related party transactions between the Company and Mr. Hattersley that would be reportable under Item 404(a) of Regulation S-K.

   Read the 8-K filing
10. Feb 7, 2023

    On February 5, 2023, Zoetis terminated Glenn David, Executive Vice President and Group President, U.S. Operations, Global Diagnostics and BioDevices at Zoetis Inc. (the “Company”), for violating company policy by engaging in a consensual personal relationship and failing to disclose it to the Company. Mr. David’s conduct did not impact our consolidated financial statements or our internal controls over financial reporting. As a result of Mr. David’s termination, he is not eligible for and will forfeit any severance benefits or future equity vesting. William (“Chip”) Dorsey, Vice President, Finance will serve as interim head of U.S. Operations and Global Diagnostics while the Company conducts a search for Mr. David’s permanent replacement. Zoetis was recently made aware of allegations of a consensual personal relationship between Mr. David and a colleague that he did not disclose.

    Read the 8-K filing
11. Oct 25, 2022

    Zoetis Inc. (the “Company”) appointed Glenn David as the Executive Vice President and Group President, U.S. Operations, Global Diagnostics and BioDevices, effective November 1, 2022. Glenn David currently serves as Executive Vice President and Group President, International Operations, Aquaculture, BioDevices and Pet Insurance. As a result of these changes, the Company has appointed Jamie Brannan, who currently serves as the Company’s President, International Operations, as the Executive Vice President and Group President, International Operations and Aquaculture (PHARMAQ), effective November 1, 2022. Wafaa Mamilli, the Company’s Chief Digital and Technology Officer, will also assume oversight of China, Brazil and Precision Animal Health, effective November 1, 2022.

    Read the 8-K filing
12. Jul 25, 2022

    On July 25, 2022, the Board of Directors (the "Board") of Zoetis Inc. (the “Company”) appointed Vanessa Broadhurst to the Board, to serve in such capacity until her successor is appointed or qualified or until her resignation or removal. In connection with the appointment of Ms. Broadhurst, the size of the Board was increased from eleven to twelve members. Ms. Broadhurst will serve on the Board’s Quality and Innovation Committee. Ms. Broadhurst was not appointed to the Board pursuant to any arrangements or understandings with any third party, and since the beginning of the last fiscal year, there have been no related party transactions between the Company and Ms. Broadhurst that would be reportable under Item 404(a) of Regulation S-K.

    Read the 8-K filing
13. Apr 21, 2022

    On April 19, 2022, Mr. Roman Trawicki, the Executive Vice President and President, Global Manufacturing and Supply at Zoetis Inc. (the “Company”) provided notice of his intention to retire from the Company. The retirement will be effective as of July 31, 2022.

    Read the 8-K filing
14. Oct 18, 2021

    On October 18, 2021, Zoetis Inc. (the “Company”) announced that Dr. Catherine Knupp, DVM, MS, the Company’s Executive Vice President and President of Research & Development, has provided notice of her intention to retire from her position, effective December 31, 2021, and that the Company has appointed Robert J. Polzer, PhD, who currently serves as the Company’s Senior Vice President of Global Therapeutics, to succeed Dr. Knupp as the Company’s Executive Vice President and President of Research & Development, effective January 1, 2022. The Company and Dr. Knupp expect Dr. Knupp to remain with the Company as an advisor assisting with the transition of her duties from January 1, 2022 until February 28, 2022.

    Read the 8-K filing
15. May 11, 2021

    On May 11, 2021, Zoetis Inc. (the “Company”) announced that Glenn C. David, the Company’s Executive Vice President and Chief Financial Officer, has been named Executive Vice President and Group President, overseeing International Operations and other business units, effective June 1, 2021. In connection with this transition, Mr. David has resigned as Chief Financial Officer and principal accounting officer of the Company, effective June 1, 2021, and the Company announced that Wetteny Joseph will join the Company as Executive Vice President, Chief Financial Officer and Head of Business Development, also effective June 1, 2021. Mr. Joseph will oversee the company’s financial management, planning and business development function, and serve as principal accounting officer of the Company. Mr.

    Read the 8-K filing

Proxy statements (DEF 14A): 2026 · 2025 · 2024 · 2023 · 2022 · 2021

From the company's 10-K XBRL data (SEC companyfacts).

People who stopped filing as an insider of this company. “Last filing” is the last Form 3/4/5, an upper bound on when they left.